CareDx Inc logo

CareDx Inc

CDNA | NASDAQ
Chart Builder DCF Calculator
$54.33
+$0.50 (+0.93%)
At close: Sep 21, 2026, 4:00 PM ET
$54.76
+$0.43 (+0.79%)
After-hours: Sep 21, 2026, 7:35 PM ET

Company Profile

CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.

Key Executives

Name Position
John Walter Hanna Jr. President, Chief Executive Officer & Director
Kashif Rathore Chief Technology Officer
Jeffrey A. Novack General Counsel & Secretary
Jessica Meng Chief Commercial Officer
Jing Huang Chief Data & Artificial Intelligence Officer
Keith S. Kennedy CFO & COO
Marica Grskovic Chief Strategy Officer
Natasha Moshirian Wagner Vice President of Corporate Communications
Nina D. Deka Head of Investor Relations
Robert N. Woodward Chief Scientific Officer
Tina Jacobsen Vice President of Investor Relations

Latest SEC Filings

Date Type Title
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 07, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 07, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 06, 2026 4 Filing
Aug 06, 2026 4 Filing
Aug 06, 2026 4 Filing
Aug 06, 2026 4 Filing
Aug 04, 2026 4 Filing
Jul 30, 2026 S-8 Filing
Jul 30, 2026 10-Q Quarterly Report
View All SEC Filings
CareDx Inc
CareDx Inc logo
Country United States
IPO Date Jul 16, 2014
Industry Medical - Diagnostics & Research
Sector Healthcare
Employees 763
CEO John Walter Hanna Jr.

Contact Details

8000 Marina Boulevard Brisbane, California 94005 United States

Stock Details

Ticker Symbol CDNA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001217234
CUSIP Number 14167L103
ISIN Number US14167L1035
SIC Code 8071

© 2026 bestshares.com. All rights reserved.